Physician profile

Rick L Simon

Podiatrist · Lansdale, PA

NPI 1699793018

$1,194.70

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$465.75

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Paratek Pharmaceuticals, INC. $304.29 2021-2024 Nuzyra
Nevro Corp. $289.22 2022-2023 Senza
Organogenesis INC. $238.81 2021-2023 Affinity
Smith+Nephew, INC. $106.71 2021
Alexion Pharmaceuticals, INC. $103.74 2019
Tactile Systems Technology INC $79.12 2023 Entre Plus, Flexitouch Plus
Grt US Holding, INC. $72.81 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Rick L Simon

$1,194.70

in general payments reported 2019-2025

Years
2019-2024
Top company
Paratek Pharmaceuticals, INC.

https://glasscript.com/doctor/924004/rick-l-simon

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.